{
    "info": {
        "nct_id": "NCT05726864",
        "official_title": "First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors",
        "inclusion_criteria": "* KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor\n* Phase 1 only: positive for circulating tumor DNA and/or elevated serum tumor biomarkers (such as CA19-9 and CEA) despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable\n* Screening CT is negative for recurrent disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Presence of tumor mutations where specific therapy is approved\n* Known brain metastases\n* Use of immunosuppressive drugs",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor",
            "criterions": [
                {
                    "exact_snippets": "KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D)",
                    "criterion": "KRAS or NRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": [
                                "KRAS G12D",
                                "KRAS G12R",
                                "KRAS G12V",
                                "KRAS G12A",
                                "KRAS G12C",
                                "KRAS G12S",
                                "KRAS G13D",
                                "NRAS G12D",
                                "NRAS G12R",
                                "NRAS G12V",
                                "NRAS G12A",
                                "NRAS G12C",
                                "NRAS G12S",
                                "NRAS G13D"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "solid tumor",
                    "criterion": "tumor type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "solid"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Screening CT is negative for recurrent disease",
            "criterions": [
                {
                    "exact_snippets": "Screening CT is negative for recurrent disease",
                    "criterion": "recurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase 1 only: positive for circulating tumor DNA and/or elevated serum tumor biomarkers (such as CA19-9 and CEA) despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable",
            "criterions": [
                {
                    "exact_snippets": "positive for circulating tumor DNA",
                    "criterion": "circulating tumor DNA",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "elevated serum tumor biomarkers (such as CA19-9 and CEA)",
                    "criterion": "serum tumor biomarkers",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "elevated"
                        }
                    ]
                },
                {
                    "exact_snippets": "prior standard therapy including surgery and chemotherapy/radiation therapy where applicable",
                    "criterion": "prior standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Presence of tumor mutations where specific therapy is approved",
            "criterions": [
                {
                    "exact_snippets": "Presence of tumor mutations where specific therapy is approved",
                    "criterion": "tumor mutations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy approval",
                            "expected_value": "specific therapy is approved for the mutation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known brain metastases",
            "criterions": [
                {
                    "exact_snippets": "Known brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of immunosuppressive drugs",
            "criterions": [
                {
                    "exact_snippets": "Use of immunosuppressive drugs",
                    "criterion": "immunosuppressive drug use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}